Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
Star Scientific, Inc. (NASDAQ: STSI) announced today that the press release issued 10/24/2012, titled "Star Scientific Announces Successful First Look at the "Flint" CRP Human Study and Provides Updated Report on ASAP Human Thyroid Study", incorrectly stated the interim results of the "Flint" CRP study. In the release, the Company reported: "After one month of supplementation, CRP levels dropped in 26% of the subjects with diabetes, compared with a drop in CRP levels in 12% of the general trial population of subjects who did not have diabetes." These figures reflected an understatement of the decrease in CRP levels after anatabine supplementation. The correct figures are as follows: 11 of 18 (61%) diabetic subjects on metformin had a CRP reduction, as did 31 of 81 (38%) subjects in the general trial population not taking metformin. Overall, 42 of 99 (42%) subjects had a decrease in CRP after only one month with anatabine supplementation.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.